MedTrace Logo

Treatment Effect According to Timing of Administration of DWP14012 40 mg

NCT04613895 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 186

Last updated 2020-11-03

No results posted yet for this study

Summary

The primary objective of this study is to establish noninferiority of efficacy of DWP14012 (40 mg once daily) based on Timing of Administration.

Conditions

  • Erosive Esophagitis

Interventions

DRUG

DWP14012

DWP14012 40 mg, orally, once daily just after a meal up to 4 weeks

DRUG

DWP14012

DWP14012 40 mg, orally, once daily before a meal up to 4 weeks

Sponsors & Collaborators

  • Hanyang University

    collaborator OTHER

  • Daewoong Pharmaceutical Co. LTD.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-17
Primary Completion
2021-05-30
Completion
2021-12-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04613895 on ClinicalTrials.gov